Wendy S. Johnson - 14 Jul 2021 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Role: Chief Development Officer
Signature: /s/ Vineet R. Jindal, Attorney-in-Fact
Issuer symbol: OKUR
Transactions as of: 14 Jul 2021
Net transactions value: -$949,756
Form type: 4
Filing time: 15 Jul 2021, 17:33:47 UTC
Previous filing: 09 Jul 2021
Next filing: 07 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPHM	Common Stock	Sale	$949,756	-111,736	-100%	$8.50	0	14 Jul 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth.

Content

The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth.